Dov Wengrower1, Benjamin Koslowsky2, Uri Peleg3, Betty Mazuz1, Leore Cohen4, Allin Ben-David5, Menahem Gross4, Eran Goldin1, Chanan Shaul3. 1. Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University Medical School, 12 Bayit St., 91031, Jerusalem, Israel. 2. Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University Medical School, 12 Bayit St., 91031, Jerusalem, Israel. binyaminkos@szmc.org.il. 3. Department of Otolaryngology Head and Neck Surgery, Shaare Zedek Medical Center, Jerusalem, Israel. 4. Department of Otolaryngology Head and Neck Surgery, Hadassah University Hospital, Jerusalem, Israel. 5. Department of Gastroenterolgy, Hadassah University Hospital, Jerusalem, Israel.
Abstract
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) has many characteristics of autoimmune diseases. Sensorineural hearing loss has been reported in many autoimmune diseases. Little is known about hearing loss in patients with IBD. METHODS: A prospective blinded comparative study was conducted over a 3-year period. IBD patients and controls underwent a complete otorhinolaryngeal examination and eudiometry test. RESULTS: Altogether 105 participants (76 patients and 29 controls) took part in this study. Mean age was 36, 51 % were males, and 40 % of the patients were presently hospitalized due to IBD exacerbation. Audiometric examination revealed that any hearing loss (mild to severe) was found in 29 (38 %) of the IBD population, compared to 4 (14 %) of the control group (p = 0.02). Extraintestinal manifestation (EIM) was present in 33/76 (43 %) of IBD patients. Any hearing loss and moderate to severe hearing loss were found in 17/33 (52 %) and 7/33 (21 %) in the EIM-positive group compared to 12/43 (28 %) and 4/43 (9 %) in the EIM-negative group (p = 0.036 and p = 0.14, respectively). Out of patients over the age of 40 with other EIMs, all 11/11 (100 %) of patients had any hearing loss compared to 8/12 (66 %) of patients over the age of 40 without other EIMs, p = 0.035. CONCLUSIONS: Hearing loss may be another EIM of IBD. It is found in 38 % of IBD patients and in up to 52 % of patients with other EIMs and increases over the age of 40. Early hearing evaluation should be recommended to these high-risk IBD patients.
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) has many characteristics of autoimmune diseases. Sensorineural hearing loss has been reported in many autoimmune diseases. Little is known about hearing loss in patients with IBD. METHODS: A prospective blinded comparative study was conducted over a 3-year period. IBD patients and controls underwent a complete otorhinolaryngeal examination and eudiometry test. RESULTS: Altogether 105 participants (76 patients and 29 controls) took part in this study. Mean age was 36, 51 % were males, and 40 % of the patients were presently hospitalized due to IBD exacerbation. Audiometric examination revealed that any hearing loss (mild to severe) was found in 29 (38 %) of the IBD population, compared to 4 (14 %) of the control group (p = 0.02). Extraintestinal manifestation (EIM) was present in 33/76 (43 %) of IBD patients. Any hearing loss and moderate to severe hearing loss were found in 17/33 (52 %) and 7/33 (21 %) in the EIM-positive group compared to 12/43 (28 %) and 4/43 (9 %) in the EIM-negative group (p = 0.036 and p = 0.14, respectively). Out of patients over the age of 40 with other EIMs, all 11/11 (100 %) of patients had any hearing loss compared to 8/12 (66 %) of patients over the age of 40 without other EIMs, p = 0.035. CONCLUSIONS:Hearing loss may be another EIM of IBD. It is found in 38 % of IBD patients and in up to 52 % of patients with other EIMs and increases over the age of 40. Early hearing evaluation should be recommended to these high-risk IBD patients.
Authors: Sivasanker Bakthavachalam; Mark S Driver; Clarke Cox; Jeffrey H Spiegel; Kenneth M Grundfast; Peter A Merkel Journal: Otol Neurotol Date: 2004-09 Impact factor: 2.311
Authors: Jeffrey Chan; Ravi Telang; Dagmara Kociszewska; Peter R Thorne; Srdjan M Vlajkovic Journal: Int J Mol Sci Date: 2022-05-06 Impact factor: 6.208